Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.

Saved in:
Bibliographic Details
Title: Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.
Authors: Szepietowski JC; Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland., Reich A; Department of Dermatology, Medical College of Rzeszów University, Rzeszów, Poland., Feldman SR; Department of Dermatology, Pathology, and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA., Pulka G; Department of Dermatology, Centrum Medyczne All-Med Badania Kliniczne, Kraków, Poland., Mekokishvili L; Petre Shotadze Tbilisi Medical Academy, School of Medicine, Tbilisi, Georgia., Tsiskarishvili N; Department of Rheumatology, Georgian-American University, Tbilisi, Georgia., Svarca I; Department of Dermatology, Health and Aesthetics LTD, Riga, Latvia., Poder A; Department of Dermatology, Kliiniliste Uuringute Keskus OU, Tartu Linn, Estonia., Singh G; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Deodhar S; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Kumar K; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Marwah A; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Loganathan S; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Wolff-Holz E; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Athalye SN; Department of Clinical Development, Salarpuria Senorita, Bengaluru, India.
Source: Expert opinion on biological therapy [Expert Opin Biol Ther] 2025 Oct; Vol. 25 (10), pp. 1121-1133. Date of Electronic Publication: 2025 Oct 21.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Comparative Study; Multicenter Study
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-7682
DOI:10.1080/14712598.2025.2576506